Sunday, May 11, 2025
5/11/2025
Anti-Cancer RNA Nanoconjugates - Working Title: ANTI-CANCER RNA NANOCONJUGATES Investigators: Robert K. DeLong, Adam Wanekaya, and Kartik Ghosh I. Abstract Nano-delivery of siRNA and RNA-based splice-site switching oligoribonucleotides (SSO) is an important new approach with chemotherapeutic potential against cancer. Here we will focus on manufacturing RNA-bound nanoparticles (RNPs). For this purpose gold, manganese or zinc-based core nanoparticles (NPs) will be prepared and RNA attached via delivery-enhancing materials (protamine or PAMAM dendrimer). In addition to a delivery advantage, this approach will greatly enhance RNA’s stability against chemical and enzymatic degradation. Stabilization of the RNA by the RNPs will be confirmed by electrophoretic and liquid chromatography analysis after exposure to accelerated chemical or enzymatic degradation assays. The RNPs will be further characterized by electron microscopy, UV, fluorescence and dynamic laser light scatter spectroscopy. Functional nuclear delivery of the RNPs will be evaluated in the Hela 705 splice-site switching assay by delivering a bound RNA oligonucleotide which overlaps the aberrant splice site, corrects splicing and switches-on Luciferase. Ultimately, as proof-of-principle to the important anti-cancer potential of this approach, biological activity of RNPs containing siRNA or SSO targeted against B-Raf—an important model cancer target will be investigated. Keywords: SSO=splice-site switching oligonucleotide, RNP=RNA nanoparticle
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).